9 reports

The drug candidate acts by blocking the histamine receptors and prevents the excess mucus production associated with ocular allergy.

  • Clinical Trial
  • Ear Disease
  • Molecular Diagnostics
  • Therapy
  • Sensorion S.A.

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Clinical Trial
  • United States
  • World
  • Product Initiative

In July 2011, Oxagen Limited announced publication of data from a Phase IIa clinical trial of its development drug OC## in the journal Clinical & Experimental Allergy.

  • Clinical Trial
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Clinical Trial
  • Eye Disease
  • United States
  • Product Initiative
  • Aldeyra Therapeutics, Inc.

One patient had a fatal SAE, which was not drug related.

  • Blood Disease
  • Clinical Trial
  • United States
  • World
  • Product Initiative

Efficacy was evaluated at Night ## (first drug administration) and after ## weeks of drug administration (Night ##).

  • Clinical Trial
  • Sleep Aid
  • Therapy
  • United States
  • Eisai Co., Ltd.

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Clinical Trial
  • Therapy
  • World
  • Product Initiative

Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women' s health; and vitamins, minerals and supplements.

  • Blood Disease
  • Clinical Trial
  • Hospital
  • Therapy
  • MediciNova, Inc.

CY-## - DRUG PROFILE DORA-## - DRUG PROFILE DRGT-## - DRUG PROFILE DRUG FOR INSOMNIA - DRUG PROFILE DRUGS TO INHIBIT ANGIOTENSIN II RECEPTOR TYPE ## FOR INSOMNIA - DRUG PROFILE EVT-## - DRUG PROFILE Drug Name C

  • Clinical Trial
  • Pharmaceutical
  • Sleep Aid
  • United States
  • Product Initiative